Healios KK (HLOSF)
0.9929
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
Healios Research and Development Expense (Quarterly): 5.235M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.235M |
| September 30, 2023 | 3.351M |
| June 30, 2023 | 3.666M |
| March 31, 2023 | 4.118M |
| December 31, 2022 | 5.540M |
| September 30, 2022 | 4.995M |
| June 30, 2022 | 9.639M |
| March 31, 2022 | 9.357M |
| December 31, 2021 | 10.05M |
| September 30, 2021 | 9.249M |
| Date | Value |
|---|---|
| June 30, 2021 | 6.395M |
| March 31, 2021 | 7.941M |
| December 31, 2020 | 9.020M |
| September 30, 2020 | 7.039M |
| June 30, 2020 | 5.994M |
| March 31, 2020 | 5.987M |
| December 31, 2019 | 8.028M |
| September 30, 2019 | 7.375M |
| June 30, 2019 | 6.997M |
| March 31, 2019 | 7.110M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.351M
Minimum
Sep 2023
10.05M
Maximum
Dec 2021
6.840M
Average
6.997M
Median
Jun 2019
Research and Development Expense (Quarterly) Benchmarks
| Takeda Pharmaceutical Co Ltd | 1.269B |
| Nxera Pharma Co Ltd | 20.74M |
| PeptiDream Inc | 6.067M |
| Stemcell Holdings Inc | -- |
| AnGes Inc | 9.032M |